Quarterly ResultMay 7, 2026, 06:13 AM
Haemonetics Q4 Revenue $346.4M, Adj. EPS $1.29; FY27 Guidance Issued
AI Summary
Haemonetics reported mixed financial results for its fourth quarter and fiscal year ended March 28, 2026. Q4 revenue increased 4.8% to $346.4 million, with adjusted EPS up 4.0% to $1.29, but GAAP EPS showed a loss of $(0.44) due to impairment charges. For the full fiscal year, revenue decreased 2.0% to $1.334 billion, while adjusted EPS reached $4.96. The company also provided fiscal 2027 guidance, projecting reported revenue growth of 4-7% and adjusted operating margin expansion.
Key Highlights
- Haemonetics Q4 fiscal 2026 revenue was $346.4 million, up 4.8% year-over-year.
- Q4 fiscal 2026 GAAP loss per diluted share was $(0.44); adjusted EPS was $1.29, up 4.0%.
- Full fiscal 2026 revenue was $1.334 billion, down (2.0)%; adjusted EPS was $4.96.
- Q4 fiscal 2026 organic ex-CSL revenue grew 8.6%, driven by Plasma (12.7%) and Hospital (6.5%).
- The company repurchased 1,579,255 shares for $100.0 million in Q4, with $325.0 million remaining.
- For fiscal 2027, Haemonetics expects reported revenue growth of 4-7% and organic revenue growth of 3-6%.
- Fiscal 2027 adjusted operating margin is projected to expand by 50-100 basis points year-over-year.
- Fiscal 2027 adjusted earnings per diluted share are expected to be comparable to revenue growth.